Slc12a8 is a nicotinamide mononucleotide transporter
Grozio A, Mills KF, Yoshino J, et al.
Key finding
Oral NMN reaches tissues intact via a dedicated intestinal transporter. Source: Grozio A, Mills KF, Yoshino J, et al. Nature Metabolism, 2019.
Summary
Identified Slc12a8 as a dedicated NMN transporter in the small intestine. Established a pharmacological basis for oral NMN bioavailability distinct from the Nam-salvage route.
For background on the compound studied here, see our NMN precursor reference.
Frequently asked questions
- What did Grozio et al. (2019) find about NMN?
- Oral NMN reaches tissues intact via a dedicated intestinal transporter. Source: Grozio A, Mills KF, Yoshino J, et al. "Slc12a8 is a nicotinamide mononucleotide transporter." Nature Metabolism, 2019.
- What kind of study is Grozio 2019?
- It is a mechanism study on NMN published in Nature Metabolism in 2019. Identified Slc12a8 as a dedicated NMN transporter in the small intestine. Established a pharmacological basis for oral NMN bioavailability distinct from the Nam-salvage route.
- Where can I read the full Grozio 2019 paper?
- The primary source is available on PubMed (PMID 30725698) and via DOI 10.1038/s42255-018-0009-4.
Access the full paper
Related research
Science · 2021
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women
NMN improved skeletal muscle insulin sensitivity and gene expression in postmenopausal women.
Cell · 2013
Declining NAD induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging
Short-term NMN restores aged-mouse muscle NAD+ and reverses pseudohypoxic mitochondrial dysfunction, implicating NAD+ decline as a causal aging driver.
Scientific Reports · 2023
Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation
12 weeks of 250 mg/day NMN in middle-aged adults raised blood NAD+ and was associated with reduced arterial stiffness (CAVI) vs. placebo.